Investing
Top Analyst Upgrades and Downgrades (BIIB, FRX, GENZ, GILD, HOLX, LVS, MOS, NVAX, RIG, TXT)
Published:
These are the top ten analyst research initiations, upgrades, and downgrades we have seen from top Wall Street firms early this Wednesday morning:
Biogen-Idec (BIIB) Started as Underperform at BofA/Merrill Lynch.
Forest Labs (FRX) Cut to Hold at Needham.
Genzyme (GENZ) Started as Buy at BofA/Merrill Lynch.
Gilead (GILD) Started as Buy at BofA/Merrill Lynch.
Hologic (HOLX) Cut to Hold at Canaccord.
Las Vegas Sands (LVS) Raised to Buy at Argus.
Mosaic (MOS) Started as Sector Perform at CIBC.
Novavax (NVAX) Cut to Market Perform at Rodman & Renshaw.
Transocean (RIG) Started as Outperform at BMO Capital.
Textron (TXT) Raised to Conviction Buy List at Goldman Sachs.
JON C. OGG
Sponsored: Want to Retire Early? Start Here
Want retirement to come a few years earlier than you’d planned? Orare you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
